Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYSandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumorsPREV STORYAlimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview